64th American Society of Hematology (ASH) Annual Meeting

Presentation Title: Initial Results from SELECT-AML-1, a Phase 2 study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Session Title: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Session Date & Time: Saturday, December 10, 2022, 5:30 – 7:30 pm CT (6:30 – 8:30 pm ET)
Location: Ernest N. Morial Convention Center, Hall D
Publication Number: 1444